科研成果详情

题名A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
作者
发表日期2020-07
发表期刊JOURNAL OF HEPATOLOGY   影响因子和分区
语种英语
原始文献类型Article
关键词MAFLD Cirrhosis Diagnostic criteria Metabolic NAFLD Steatohepatitis Diabetes Obesity
其他关键词NONALCOHOLIC STEATOHEPATITIS ; HISTOLOGIC FEATURES ; NATURAL-HISTORY ; HEALTHY OBESE ; MANAGEMENT ; DIAGNOSIS ; NAFLD ; PROGRESSION ; PREVALENCE ; PREVENTION
摘要The exclusion of other chronic liver diseases including excess alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, positive criteria to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
资助项目Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [APP1053206, APP1149976, APP1107178, APP1108422]; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust; University of Birmingham
出版者ELSEVIER
出版地AMSTERDAM
ISSN0168-8278
EISSN1600-0641
卷号73期号:1页码:202-209
DOI10.1016/j.jhep.2020.03.039
页数8
WOS类目Gastroenterology & Hepatology
WOS研究方向Gastroenterology & Hepatology
WOS记录号WOS:000563494500023
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
PubMed ID32278004
SCOPUSEID2-s2.0-85083788691
ESI热点论文2020-09 ; 2020-11 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-09 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09
ESI高被引论文2020-09 ; 2020-11 ; 2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09 ; 2024-11
自科自定义期刊分类T2(B)类
通讯作者地址[Eslam, Mohammed]Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital and University of Sydney,Westmead,2145,Australia ; [Newsome, Philip N.]National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham,Birmingham,United Kingdom ; [Ratziu, Vlad]Hôpital Pitié-Salpétrière,47-83 Bd de l'Hôpital,Paris,75013,France
Scopus学科分类Hepatology
TOP期刊TOP期刊
引用统计
被引频次:1076[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/20913
专题附属第一医院_感染内科
通讯作者Eslam, Mohammed; Newsome, Philip N.; Ratziu, Vlad
作者单位
1.Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital and University of Sydney,NSW,Australia;
2.National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham,UK; Centre for Liver and Gastrointestinal Research,Institute of Immunology and Immunotherapy,University of Birmingham,UK; Liver Unit,University Hospitals Birmingham NHS Foundation Trust,Birmingham,United Kingdom;
3.Department of Hepatology,Institute of Liver and Biliary Sciences,New Delhi,India;
4.Translational & Clinical Research Institute,Faculty of Medical Sciences,Newcastle University,Newcastle upon Tyne,United Kingdom; Newcastle NIHR Biomedical Research Centre,Newcastle upon Tyne Hospitals NHS Foundation Trust,Newcastle upon Tyne,United Kingdom;
5.Section of Endocrinology,Diabetes and Metabolism,Department of Medicine,University and Azienda Ospedaliera Universitaria Integrata of Verona,Verona,Italy;
6.UCM Digestive Diseases,Virgen del Rocio University Hospital,Instituto de Biomedicina de Sevilla,CIBEREHD,University of Seville,Sevilla,Spain;
7.School of Public Health,University of Haifa,Haifa,Israel; Department of Gastroenterology,Tel Aviv Medical Center,Tel Aviv,Israel;
8.Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong;
9.University Clinic for Visceral Surgery and Medicine,Inselspital,University of Bern,Switzerland; Department of Biomedical Research,University of Bern,Switzerland;
10.Department of Medicine,University Medical Centre,Johannes Gutenberg University Mainz,Germany;
11.Division of Gastroenterology,Department of Medicine,Kurume University School of Medicine,Kurume,Japan;
12.Departamento de Gastroenterología,Escuela de Medicina,Pontificia Universidad Católica de Chile,Santiago,Chile and Centro de Envejecimiento y Regeneracion (CARE),Departamento de Biologia Celular y Molecular,Facultad de Ciencias Biologicas Pontificia Universidad Catolica de Chile,Santiago,Chile;
13.Department of Pathophysiology and Transplantation,Università degli Studi di Milano,and Translational Medicine,Department of Transfusion Medicine and Hematology,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Milano,Italy;
14.Hepatology and Gastroenterology Unit,Internal Medicine Department,Faculty of Medicine,Mansoura University,Egypt;
15.Liver Center,Italian Liver Foundation,Trieste,Italy;
16.Department of Medicine,University of Helsinki and Helsinki University Hospital and Minerva Foundation Institute for Medical Research,Helsinki,Finland;
17.Center for Fatty Liver,Department of Gastroenterology,Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai Key Lab of Pediatric Gastroenterology and Nutrition,Shanghai,China;
18.Department of Hepatology & Gastroenterology,Aarhus University Hospital,Aarhus,Denmark;
19.Department of Gastroenterology,School of Medicine,Marmara University,Istanbul,Turkey; Institute of Gastroenterology,Marmara University,Istanbul,Turkey;
20.Clínica Universitária de Gastrenterologia,Laboratório de Nutrição,Faculdade de Medicina,Universidade de Lisboa,Portugal;
21.Department of Gastroenterology,University of Sao Paulo,School of Medicine,Sao Paulo,Brazil;
22.Department of Pathology,Physiology and Imaging,Beaujon Hospital Paris Diderot University,Paris,France;
23.Medical School,Sir Charles Gairdner Hospital Unit,University of Western Australia,Nedlands,Australia;
24.NAFLD Research Center,Department of Hepatology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; Institute of Hepatology,Wenzhou Medical University,Wenzhou,China;
25.Department of Gastroenterology,Hepatology and Endemic Medicine,Faculty of Medicine,Minia University Hospitals,Minya,Egypt;
26.Gastroenterology and Hepatology Unit,Department of Medicine,Faculty of Medicine,University of Malaya,Kuala Lumpur,Malaysia;
27.Liver Research Unit,Medica Sur Clinic & Foundation and Faculty of Medicine,National Autonomous University of Mexico,Mexico City,Mexico;
28.Department of Internal Medicine,Yonsei University College of Medicine,Seoul,South Korea;
29.Université Paris VII,Inserm Umr 1149,Centre de Recherche Sur L'inflammation,Paris,France;
30.Division of Gastroenterology and Hepatology,Department of Medical Sciences,University of Turin,Turin,Italy;
31.Sorbonne Université,Assistance Publique-Hôpitaux de Paris,Hôpital Pitié Salpêtrière-,Institute of Cardiometabolism and Nutrition (ICAN),Paris,France
推荐引用方式
GB/T 7714
Eslam, Mohammed,Newsome, Philip N.,Sarin, Shiv K.,et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. JOURNAL OF HEPATOLOGY,2020,73(1):202-209.
APA Eslam, Mohammed., Newsome, Philip N.., Sarin, Shiv K.., Anstee, Quentin M.., Targher, Giovanni., ... & George, Jacob. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. JOURNAL OF HEPATOLOGY, 73(1), 202-209.
MLA Eslam, Mohammed,et al."A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".JOURNAL OF HEPATOLOGY 73.1(2020):202-209.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
百度学术
百度学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
必应学术
必应学术中相似的文章
[Eslam, Mohammed]的文章
[Newsome, Philip N.]的文章
[Sarin, Shiv K.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。